Tuan Huynh

Tuan Huynh is an Equity Analyst at ArrowMark Partners in Denver, Colorado, where he focuses on investment research, analysis, and portfolio recommendations within the healthcare sector, particularly biotechnology, pharmaceuticals, therapeutics, and life sciences. In his current capacity, he leverages deep industry knowledge to evaluate growth opportunities and support the firm’s investments in innovative healthcare companies at various stages of development.

Huynh's career spans nearly two decades, including prior roles as Senior Equity Research Associate at Janus Capital Group and Fee and Expense Analyst at Lipper, where he honed his expertise in fundamental equity analysis and investment due diligence. His background demonstrates a consistent focus on public equity markets and health-related asset classes, strengthening ArrowMark's capabilities in sourcing and assessing high-growth healthcare investments.

He holds a Master of Business Administration in Business Management and Finance as well as a Bachelor of Science in Finance, both from the University of Colorado Denver. Huynh’s analytical rigor and specialized focus on healthcare equities have contributed to ArrowMark Partners’ robust research-driven approach to growth equity and alternative investment strategies.